Clinical Trials
23 trialsNCT04348747 2026-05-11
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
Roswell Park Cancer Institute
Phase 2 Recruiting
NCT03797326 2026-05-04
LEAP-005
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT07523529 2026-04-13
SELECT-2CAR
Beijing Biotech
Phase 1/2 Recruiting
NCT02595905 2026-04-08
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
National Cancer Institute (NCI)
Phase 2 Completed
NCT04789668 2026-03-18
Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT07458113 2026-03-09
BERLIN
Yale University
Phase 2 Not yet recruiting
NCT05296564 2025-10-02
Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers
Hadassah Medical Organization
Phase 1/2 Recruiting
NCT05388435 2025-05-04
Safety, Tolerability, PK/PD & Preliminary Efficacy of SKL27969 in Advanced Solid Tumors Patients
SK Life Science, Inc.
Phase 1/2 Terminated
NCT06793332 2025-01-27
BALISTA
Fudan University
Phase 2 Recruiting
NCT03881605 2025-01-20
SYMPToM
Sunnybrook Health Sciences Centre
Phase NA Active not recruiting
NCT05255666 2023-07-11
Combination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM)
Washington University School of Medicine
Phase 2 Withdrawn
NCT04434560 2022-07-26
Neoadjuvant Immunotherapy in Brain Metastases
Duke University
Phase 2 Terminated
NCT02201381 2022-07-18
METRICS
Health Clinics Limited
Phase 3 Withdrawn
NCT02000882 2022-02-07
STAR Cape+BKM120 MBC With Brain Met
US Oncology Research
Phase 2 Completed
NCT01631552 2021-08-12
Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer
Gilead Sciences
Phase 1/2 Completed
NCT02260531 2021-05-20
Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain Metastases
Dana-Farber Cancer Institute
Phase 2 Completed
NCT03617341 2020-10-27
Brain Monitoring for High Risk of Brain Metastases in Metastatic Breast Cancer
Yonsei University
Unknown
NCT02048059 2020-02-25
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Angiochem Inc
Phase 2 Completed
NCT02576665 2020-02-07
A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)
Tocagen Inc.
Phase 1 Terminated
NCT02365662 2018-03-30
A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor
AbbVie
Phase 1 Terminated
NCT02448576 2017-06-01
PCI in Advanced Triple Negative Breast Cancer Patients Who Response to 1st Line Chemotherapy
Sun Yat-sen University
Phase NA Unknown
NCT01173497 2016-03-17
A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis
Sanofi
Phase 2 Completed
NCT00031681 2013-09-30
7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
National Cancer Institute (NCI)
Phase 1 Completed